Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers. / Tvedskov, Tove Holst Filtenborg; Jensen, Maj-Britt; Balslev, Eva; Garne, Jens Peter; Vejborg, Ilse; Christiansen, Peer; Ejlertsen, Bent; Kroman, N.

I: Acta Oncologica, Bind 55, Nr. 4, 2016, s. 455-9.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Tvedskov, THF, Jensen, M-B, Balslev, E, Garne, JP, Vejborg, I, Christiansen, P, Ejlertsen, B & Kroman, N 2016, 'Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers', Acta Oncologica, bind 55, nr. 4, s. 455-9. https://doi.org/10.3109/0284186X.2015.1094186

APA

Tvedskov, T. H. F., Jensen, M-B., Balslev, E., Garne, J. P., Vejborg, I., Christiansen, P., Ejlertsen, B., & Kroman, N. (2016). Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers. Acta Oncologica, 55(4), 455-9. https://doi.org/10.3109/0284186X.2015.1094186

Vancouver

Tvedskov THF, Jensen M-B, Balslev E, Garne JP, Vejborg I, Christiansen P o.a. Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers. Acta Oncologica. 2016;55(4):455-9. https://doi.org/10.3109/0284186X.2015.1094186

Author

Tvedskov, Tove Holst Filtenborg ; Jensen, Maj-Britt ; Balslev, Eva ; Garne, Jens Peter ; Vejborg, Ilse ; Christiansen, Peer ; Ejlertsen, Bent ; Kroman, N. / Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers. I: Acta Oncologica. 2016 ; Bind 55, Nr. 4. s. 455-9.

Bibtex

@article{a7d950de40c1403cb2964bfa543376d5,
title = "Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers",
abstract = "BACKGROUND: Symptomatic breast cancers may be more aggressive as compared to screen-detected breast cancers. This could favor axillary lymph node dissection (ALND) in patients with symptomatic breast cancer and positive sentinel nodes.METHOD: We identified 955 patients registered in the Danish Breast Cancer Cooperative Group (DBCG) Database in 2008 - 2010 with micrometastases (773) or isolated tumor cells (ITC) (182) in the sentinel node. Patients were cross-checked in the Danish Quality Database of Mammography Screening and 481 patients were identified as screen-detected cancers. The remaining 474 patients were considered as having symptomatic cancers. Multivariate analyses of the risk of non-sentinel node metastases were performed including known risk factors for non-sentinel node metastases as well as method of detection.RESULTS: 18% of the patients had metastases in non-sentinel nodes. This was evenly distributed between patients with symptomatic and screen-detected cancers; 18.5% vs 17.5% (OR 1.07; 95% CI 0.77-1.49; p = 0.69). In patients with micrometastases 21% had non-sentinel node metastases in the group with symptomatic cancers compared to 19% of patients with screen-detected cancers. This difference was not significant (OR 1.16; 95% CI 0.81-1.65, p = 0.43). Neither the multivariate analysis showed an increased risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected cancers (OR 1.12, CI 0.77-1.62, p = 0.55). In patients with ITCs 8% of patients with symptomatic cancers had non-sentinel node metastases compared to 13% of patients with screen-detected cancers. This difference was not significant (OR 0.58; 95% CI 0.22-1.54, p = 0.27). In the multivariate analysis, the risk of non-sentinel node metastases was still not significantly increased in patients with symptomatic cancers compared to screen-detected cancers (OR 0.45; 95% CI 0.16-1.27, p = 0.13).CONCLUSION: We did not find any clinically relevant difference in the risk of non-sentinel node metastases between patients with symptomatic and screen-detected cancers with micrometastases or ITC in the sentinel node.",
keywords = "Journal Article",
author = "Tvedskov, {Tove Holst Filtenborg} and Maj-Britt Jensen and Eva Balslev and Garne, {Jens Peter} and Ilse Vejborg and Peer Christiansen and Bent Ejlertsen and N Kroman",
year = "2016",
doi = "10.3109/0284186X.2015.1094186",
language = "English",
volume = "55",
pages = "455--9",
journal = "Acta Oncologica",
issn = "1100-1704",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers

AU - Tvedskov, Tove Holst Filtenborg

AU - Jensen, Maj-Britt

AU - Balslev, Eva

AU - Garne, Jens Peter

AU - Vejborg, Ilse

AU - Christiansen, Peer

AU - Ejlertsen, Bent

AU - Kroman, N

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Symptomatic breast cancers may be more aggressive as compared to screen-detected breast cancers. This could favor axillary lymph node dissection (ALND) in patients with symptomatic breast cancer and positive sentinel nodes.METHOD: We identified 955 patients registered in the Danish Breast Cancer Cooperative Group (DBCG) Database in 2008 - 2010 with micrometastases (773) or isolated tumor cells (ITC) (182) in the sentinel node. Patients were cross-checked in the Danish Quality Database of Mammography Screening and 481 patients were identified as screen-detected cancers. The remaining 474 patients were considered as having symptomatic cancers. Multivariate analyses of the risk of non-sentinel node metastases were performed including known risk factors for non-sentinel node metastases as well as method of detection.RESULTS: 18% of the patients had metastases in non-sentinel nodes. This was evenly distributed between patients with symptomatic and screen-detected cancers; 18.5% vs 17.5% (OR 1.07; 95% CI 0.77-1.49; p = 0.69). In patients with micrometastases 21% had non-sentinel node metastases in the group with symptomatic cancers compared to 19% of patients with screen-detected cancers. This difference was not significant (OR 1.16; 95% CI 0.81-1.65, p = 0.43). Neither the multivariate analysis showed an increased risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected cancers (OR 1.12, CI 0.77-1.62, p = 0.55). In patients with ITCs 8% of patients with symptomatic cancers had non-sentinel node metastases compared to 13% of patients with screen-detected cancers. This difference was not significant (OR 0.58; 95% CI 0.22-1.54, p = 0.27). In the multivariate analysis, the risk of non-sentinel node metastases was still not significantly increased in patients with symptomatic cancers compared to screen-detected cancers (OR 0.45; 95% CI 0.16-1.27, p = 0.13).CONCLUSION: We did not find any clinically relevant difference in the risk of non-sentinel node metastases between patients with symptomatic and screen-detected cancers with micrometastases or ITC in the sentinel node.

AB - BACKGROUND: Symptomatic breast cancers may be more aggressive as compared to screen-detected breast cancers. This could favor axillary lymph node dissection (ALND) in patients with symptomatic breast cancer and positive sentinel nodes.METHOD: We identified 955 patients registered in the Danish Breast Cancer Cooperative Group (DBCG) Database in 2008 - 2010 with micrometastases (773) or isolated tumor cells (ITC) (182) in the sentinel node. Patients were cross-checked in the Danish Quality Database of Mammography Screening and 481 patients were identified as screen-detected cancers. The remaining 474 patients were considered as having symptomatic cancers. Multivariate analyses of the risk of non-sentinel node metastases were performed including known risk factors for non-sentinel node metastases as well as method of detection.RESULTS: 18% of the patients had metastases in non-sentinel nodes. This was evenly distributed between patients with symptomatic and screen-detected cancers; 18.5% vs 17.5% (OR 1.07; 95% CI 0.77-1.49; p = 0.69). In patients with micrometastases 21% had non-sentinel node metastases in the group with symptomatic cancers compared to 19% of patients with screen-detected cancers. This difference was not significant (OR 1.16; 95% CI 0.81-1.65, p = 0.43). Neither the multivariate analysis showed an increased risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected cancers (OR 1.12, CI 0.77-1.62, p = 0.55). In patients with ITCs 8% of patients with symptomatic cancers had non-sentinel node metastases compared to 13% of patients with screen-detected cancers. This difference was not significant (OR 0.58; 95% CI 0.22-1.54, p = 0.27). In the multivariate analysis, the risk of non-sentinel node metastases was still not significantly increased in patients with symptomatic cancers compared to screen-detected cancers (OR 0.45; 95% CI 0.16-1.27, p = 0.13).CONCLUSION: We did not find any clinically relevant difference in the risk of non-sentinel node metastases between patients with symptomatic and screen-detected cancers with micrometastases or ITC in the sentinel node.

KW - Journal Article

U2 - 10.3109/0284186X.2015.1094186

DO - 10.3109/0284186X.2015.1094186

M3 - Journal article

C2 - 26452696

VL - 55

SP - 455

EP - 459

JO - Acta Oncologica

JF - Acta Oncologica

SN - 1100-1704

IS - 4

ER -

ID: 164442698